Los puntos clave no están disponibles para este artículo en este momento.
The CAZ-AVI + ATM combination offers a therapeutic advantage compared to OAAs for patients with BSI due to MBL-producing Enterobacterales. Further studies are warranted.
Falcone et al. (Tue,) studied this question.